About OGIVRI

OGIVRI is a prescription medication containing the active ingredient Trastuzumab, a monoclonal antibody that targets the HER2 protein. It is used in the treatment of certain types of breast cancer, including HER2-positive breast cancer, and gastric cancer.

Key Benefits & Uses

Treatment of HER2-positive breast cancer in combination with chemotherapy (e.g., doxorubicin, paclitaxel, or docetaxel) for early breast cancer
Treatment of HER2-positive breast cancer in combination with chemotherapy (e.g., fluorouracil, doxorubicin, and cyclophosphamide) followed by a taxane for metastatic breast cancer
Treatment of HER2-positive gastric cancer in combination with chemotherapy (e.g., cisplatin and capecitabine)

Active Ingredient & Action

Trastuzumab works by binding to the HER2 protein on the surface of cancer cells, which can help slow or stop the growth of the cancer. It is administered intravenously and can take several weeks to reach its full effect.

Important Notes

OGIVRI should only be used under the guidance of a qualified healthcare professional. Patients should be closely monitored for signs of cardiac dysfunction, infusion reactions, and pulmonary toxicity. It is essential to follow the recommended dosing schedule and to report any side effects or concerns to a healthcare provider promptly.